Patent intelligence · US
US 12180300
Targeting moiety-drug grafted immune cell compositions and methods of use
Targeting moiety-drug grafted immune cell compositions and methods of use
Patent details — US 12180300
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2024
- Expiration
- Dec 26, 2044
- Claims
- 8
- CPC classes
- A61K, A61K47/60, A61K47/68033, A61K47/6849
Quick answer
US 12180300 (Targeting moiety-drug grafted immune cell compositions and methods of use) is held by Arizona Board of Regents on Behalf of the University of Arizona. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K47/60, A61K47/68033, A61K47/6849, A61K47/6851, A61K47/6855
More from Arizona Board of Regents on Behalf of the University of Arizona
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 12180300?
US 12180300 (Targeting moiety-drug grafted immune cell compositions and methods of use) is held by Arizona Board of Regents on Behalf of the University of Arizona. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12180300?
Arizona Board of Regents on Behalf of the University of Arizona is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 12180300 expire?
Our index shows an expiration date of Dec 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.